In the past three years the COVID pandemic dramatized just how crucial our industry is to the nation’s health, economy and American productivity. But on Capitol Hill, and across the country, we have been used as a political football. Just last year a bill was signed into law that will delay or deny future cures by allowing government price fixing which will result in fewer investments.

***[COMPANY]*** is a proud member of the Biotechnology Innovation Organization (BIO)—and many members of our team rely on [Good Day BIO](https://www.bio.org/gooddaybio-archive), BIO’s daily newsletter that takes no more than 3 minutes to scan every morning with the day’s top news and why it matters to our industry.

So, today, we’re encouraging all of you to sign up to receive Good Day BIO in your inbox each morning and give us 5 minutes each day to keep up to date and be alerted to when you can take action and make a difference — [click here to subscribe now](https://www.bio.org/goodday) (It’s free!).

Here’s what you’ll get:

* The day’s top stories across health and pharmaceuticals, agriculture and environment, biomanufacturing and the bioeconomy, and federal, state, and international policy—in just 1,000 words (five minutes or less).
* BIO’s take on breaking news and must-read stories from around the world—with simple ways to explain our industry to family and friends.
* Exclusive reporting about stories no one else is covering and trustworthy thought leadership you’ll want to share.

As we gear up for activity this fall on a number of priority issues like [PBM](https://www.bio.org/gooddaybio-archive/pbm-bills-advance-house-and-senate) Reform and reauthorization of [the Pandemic All-Hazards Preparedness Act (PAHPA)](https://www.bio.org/gooddaybio-archive/pahpa-moves-forward), it’s more important than ever for the biotech community to get the true story and insights on industry public policy as easily, quickly and efficiently as possible. Good Day BIO can help.

[Click here to sign up now.](https://www.bio.org/goodday)